Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
miRagen Therapeutics, Inc., a biopharmaceutical company discovering and developing innovative microRNA (miRNA)-targeting therapeutics, today announced the appointments of Christopher J. Morl, M.B.A., B.Sc. (Hons), as Chief Business Officer and Aimee L. Jackson, Ph.D., as Director of Target Development. Mr. Morl and Dr. Jackson are biotech and pharmaceutical industry veterans and bring significant strategic and technical experience to the company’s senior leadership team.
Help employers find you! Check out all the jobs and post your resume.
